Vox Sanguinis International Forum on application of fetal blood grouping

Daniels, Geoff; Finning, Kirstin; Lozano, M.; Hyland, Catherine A.; Liew, Yew‐Wah; Powley, Tanya; Castilho, Lilian; Bub, Carolina Bonet; Kutner, José Mauro; Clausen, Frederik Banch; Christiansen, Mette; Sulin, Kati; Haimila, Katri; Legler, T. J.; Lambert, Mark; Ryan, Helen; Loingsigh, S. Ní; Matteocci, Antonella; Pierelli, Luca; Drnovšek, Tadeja Dovč; Bricl, Irena; Nogués, Núria; Muñiz‐Díaz, Eduardo; Olsson, Martin L.; Wikman, Agneta; Haas, Masja de; Schoot, C. Ellen van der; Massey, Edwin; Westhoff, Connie M.

doi:10.1111/vox.12615

Cited by 9 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,36 In contrast, in the United States, questions remain about the clinical utility of noninvasive testing to avoid adverse events associated with amniocentesis, and test availability is limited. 37,38…”

Section: Fetal Testingmentioning

confidence: 99%

Blood group genotyping

Westhoff

2019

Blood

View full text Add to dashboard Cite

Genomics is affecting all areas of medicine. In transfusion medicine, DNA-based genotyping is being used as an alternative to serological antibody-based methods to determine blood groups for matching donor to recipient. Most antigenic polymorphisms are due to single nucleotide polymorphism changes in the respective genes, and DNA arrays that target these changes have been validated by comparison with antibody-based typing. Importantly, the ability to test for antigens for which there are no serologic reagents is a major medical advance to identify antibodies and find compatible donor units, and can be life-saving. This review summarizes the evolving use and applications of genotyping for red cell and platelet blood group antigens affecting several areas of medicine. These include prenatal medicine for evaluating risk of fetal or neonatal disease and candidates for Rh-immune globulin; transplantation for bone marrow donor selection and transfusion support for highly alloimmunized patients and for confirmation of A2 status of kidney donors; hematology for comprehensive typing for patients with anemia requiring chronic transfusion; and oncology for patients receiving monoclonal antibody therapies that interfere with pretransfusion testing. A genomics approach allows, for the first time, the ability to routinely select donor units antigen matched to recipients for more than ABO/RhD to reduce complications. Of relevance, the growth of whole-genome sequencing in chronic disease and for general health will provide patients’ comprehensive extended blood group profile as part of their medical record to be used to inform selection of the optimal transfusion therapy.

show abstract

Section: Fetal Testingmentioning

confidence: 99%

Blood group genotyping

Westhoff

2019

Blood

View full text Add to dashboard Cite

show abstract

“…As a screening to guide prophylaxis, non-invasive prenatal testing of fetal RHD has been introduced as a nationwide clinical service in Denmark [33,34], the Netherlands [35], Finland [36], Norway [37], Germany, Sweden [38], Slovenia and the UK [39,40], with other countries in the process of implementation [41,42]. Evaluations of national programmes have demonstrated high test accuracy, with sensitivities of >99Á9% around 25 weeks of gestation and >99% from week 10 [12,43].…”

Section: Non-invasive Prenatal Testing Of Fetal Rhdmentioning

confidence: 99%

Cell‐free fetalDNAand fetal blood group genotyping: non‐invasive prenatal testing

Clausen

2019

ISBT Science Series

View full text Add to dashboard Cite

In transfusion medicine and clinical immunology, cell-free fetal DNA (cffDNA) is analysed from maternal plasma of pregnant women to predict fetal blood groups with the purpose of (1) assessing the risk of haemolytic disease of the fetus and newborn (HDFN) in immunized women and (2) guiding targeted Rh prophylaxis in non-immunized RhD-negative women. National programmes for guiding prophylaxis are now implemented in around 6-7 European countries; assay accuracy is very high, with sensitivities of 99Á9%. Sensitivity is challenged by low quantities of cffDNA, especially in early pregnancy. Specificity is challenged by the polymorphic Rh blood group system, where careful attention is needed to navigate among the many RHD variants that may complicate cffDNA analysis and interpretation of results, especially in populations with mixed ethnicities. However, fetal RHD testing is feasible when implemented with careful attention to these issues. The success of predicting fetal RhD and its successful clinical implementation should encourage widespread implementation. For blood groups that are determined by SNPs, such as KEL or Rhc, novel techniques such as next-generation sequencing and droplet digital PCR are now providing accurate non-invasive prediction of these fetal blood groups. Future work on non-invasive prenatal testing of fetal blood groups determined by SNPs may consolidate the application for cell-free DNA testing for such targets. At ISBT, the newly formed cfDNA subgroup of the Red Cell Immunogenetics and Blood Group Terminology Working Party will work to facilitate clinical applications, implementation and evaluation of cell-free DNA testing.

show abstract

“…The strategies adopted for RHD analysis by molecular methods vary widely in different countries and laboratories (Daniels et al, ). In general, methods that detect more than one region of RHD are necessary, and in case of populations with African ancestry, the inclusion of a test for RHDψ evaluation is imperative (Daniels, ).…”

Section: Discussionmentioning

confidence: 99%

Molecular analysis of the RHD pseudogene by duplex real‐time polymerase chain reaction

Silva-Malta

Santos

Gonçalves

et al. 2019

Transfusion Medicine

View full text Add to dashboard Cite

Objectives:In this study, we aimed to present a strategy for the detection of the RHD pseudogene (RHD ) based on a real-time polymerase chain reaction (PCR) assay. Background:The D-negative phenotype is associated with many genetic alterations. In populations with African ancestry, this phenotype commonly results from the silent variant RHD . The evaluation of RHD is essential for correct inference of the RhD phenotype in order to avoid false-positive results. Methods:We utilised a new method for the simultaneous detection of RHD and a fragment from exon 5 of the wild-type RHD gene based on duplex real-time PCR assay. Results:The PCR assay allowed specific detection of RHD . There was complete agreement between the results generated by the new test and the results generated by molecular analysis performed using end-point PCR methods previously described. Conclusions:The assay developed is easy to execute and presents the potential for routine use at blood banks and other associated facilities where it is desired to determine the presence of RHD .

show abstract

Vox Sanguinis International Forum on application of fetal blood grouping

Cited by 9 publications

References 24 publications

Blood group genotyping

Blood group genotyping

Cell‐free fetalDNAand fetal blood group genotyping: non‐invasive prenatal testing

Molecular analysis of the RHD pseudogene by duplex real‐time polymerase chain reaction

Contact Info

Product

Resources

About